Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
DRRX DURECT Corporation daily Stock Chart
DRRX [NASD]
DURECT Corporation
Healthcare | Drug Manufacturers - Other | USA
financial highlights | statements
Index- P/E- EPS (ttm)-0.15 Insider Own1.10% Shs Outstand161.66M Perf Week3.50%
Market Cap115.78M Forward P/E- EPS next Y-0.18 Insider Trans5.64% Shs Float155.93M Perf Month26.00%
Income-24.20M PEG- EPS next Q-0.04 Inst Own44.70% Short Float2.37% Perf Quarter-4.61%
Sales19.20M P/S6.03 EPS this Y-523.00% Inst Trans-3.11% Short Ratio7.24 Perf Half Y-19.54%
Book/sh0.09 P/B7.96 EPS next Y0.00% ROA-44.70% Target Price3.27 Perf Year-63.27%
Cash/sh0.18 P/C4.05 EPS next 5Y20.00% ROE-108.90% 52W Range0.46 - 2.25 Perf YTD48.25%
Dividend- P/FCF- EPS past 5Y5.30% ROI-58.30% 52W High-68.17% Beta1.81
Dividend %- Quick Ratio3.40 Sales past 5Y3.90% Gross Margin78.00% 52W Low55.70% ATR0.07
Employees88 Current Ratio3.70 Sales Q/Q17.10% Oper. Margin- RSI (14)53.43 Volatility7.59% 13.03%
OptionableYes Debt/Eq0.00 EPS Q/Q18.60% Profit Margin- Rel Volume0.74 Prev Close0.72
ShortableYes LT Debt/Eq1.44 EarningsMay 07 AMC Payout- Avg Volume511.21K Price0.72
Recom- SMA205.49% SMA506.28% SMA200-15.60% Volume377,145 Change-0.08%
Mar-06-18Upgrade H.C. Wainwright Neutral → Buy $3.50
Oct-20-17Reiterated Laidlaw Buy $3 → $2
Oct-20-17Downgrade Stifel Buy → Hold $3 → $0.90
Oct-20-17Downgrade H.C. Wainwright Buy → Neutral
Jul-12-17Upgrade Stifel Hold → Buy $1.25 → $3
Feb-28-17Resumed H.C. Wainwright Buy $3
Apr-25-16Initiated Rodman & Renshaw Buy $4
May-01-15Reiterated Stifel Buy $1.50 → $2.50
May-01-15Reiterated Cantor Fitzgerald Buy $2.50 → $3
Mar-25-13Initiated Stifel Buy $3
Nov-01-12Downgrade C.K. Cooper Buy → Hold $3
Aug-17-12Initiated C.K. Cooper Buy $3
Jun-23-09Initiated Caris & Company Buy $5
Mar-26-09Initiated Wedbush Morgan Hold
Feb-10-09Reiterated Jefferies & Co Buy $6.50 → $5
Mar-18-08Initiated Punk, Ziegel & Co Mkt Perform $5
Mar-14-08Initiated RBC Capital Mkts Outperform
Sep-20-07Initiated Broadpoint Capital Strong Buy $10.25
May-17-19 10:50AM  DRRX: Highly Compelling Initial Ph2a DUR-928 Alcoholic Hepatitis Data. Final Data Later This Year Could Be Value Inflection Event Zacks Small Cap Research
03:02AM  Edited Transcript of DRRX earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
May-16-19 04:15PM  DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 PR Newswire +7.34%
May-08-19 11:40AM  DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial PR Newswire +6.98%
07:53AM  The Daily Biotech Pulse: Daiichi's Positive Breast Cancer Trial, Supernus Slumps, Axovant Reverse Split Benzinga
06:30AM  DURECT Corp. to Host Earnings Call ACCESSWIRE
05:04AM  Durect: 1Q Earnings Snapshot Associated Press
May-07-19 09:03PM  DURECT Corporation Announces Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial PR Newswire
05:42PM  DURECT Corporation Announces First Quarter 2019 Financial Results and Update of Programs PR Newswire
08:20AM  The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex Benzinga
May-03-19 01:26PM  DURECT Corporation to Present Preliminary Data from the Ongoing DUR-928 Alcoholic Hepatitis Phase 2a Trial and Report First Quarter 2019 Financial Results PR Newswire +49.01%
Apr-25-19 08:00AM  DURECT Appoints Two New Board Members PR Newswire
Apr-22-19 03:24PM  DURECT Corporation (NASDAQ:DRRX): What's The Analyst Consensus Outlook? Simply Wall St.
Apr-01-19 08:00AM  DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH PR Newswire
Mar-27-19 08:00AM  DURECT Announces Patient Enrollment in Phase 1b Clinical Trial of Oral DUR-928 in Patients with Non-Alcoholic Steatohepatitis (NASH) PR Newswire
Mar-21-19 08:00AM  DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis PR Newswire
Mar-13-19 07:55PM  Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents
04:00PM  DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year Zacks Small Cap Research
Mar-08-19 09:48PM  Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
Mar-07-19 04:05PM  DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs PR Newswire -5.79%
Mar-04-19 08:00AM  DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call PR Newswire -5.43%
Feb-27-19 07:00AM  DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter PR Newswire
Feb-26-19 12:00PM  DURECT Corporation (NASDAQ:DRRX): Time For A Financial Health Check Simply Wall St.
Feb-22-19 07:20AM  Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT New Research Emphasizes Economic Growth GlobeNewswire
Feb-21-19 08:00AM  DURECT Corporation to Participate in the Berenberg NASH Day PR Newswire
Jan-24-19 07:00AM  Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug GlobeNewswire
Jan-11-19 11:45AM  DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications Zacks Small Cap Research
Jan-10-19 07:51AM  Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Jan-07-19 07:30AM  DURECT Corporation Provides Corporate Update PR Newswire -13.10%
Jan-04-19 06:59AM  Heres What We Think About DURECT Corporations (NASDAQ:DRRX) CEO Pay Simply Wall St. +27.52%
Jan-03-19 04:30PM  DURECT Corporation Announces Investor Call to Provide Corporate Update PR Newswire -5.22%
Dec-19-18 08:00AM  Commercial Launch Plans Announced for PERSERIS (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults PR Newswire
Dec-17-18 08:00AM  DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist PR Newswire
Nov-30-18 07:55AM  Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -5.67%
Nov-19-18 08:00AM  DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients PR Newswire
Nov-16-18 02:30PM  DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream Zacks Small Cap Research
Nov-13-18 01:44PM  Could DURECT Corporations (NASDAQ:DRRX) Investor Composition Influence The Stock Price? Simply Wall St. -5.61%
Nov-07-18 05:13PM  Durect: 3Q Earnings Snapshot Associated Press +5.19%
04:01PM  DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
Nov-01-18 04:15PM  DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call PR Newswire
Oct-25-18 08:00AM  DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings PR Newswire +7.45%
Oct-23-18 08:20AM  Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-01-18 08:00AM  DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer PR Newswire
Sep-25-18 08:00AM  DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire +5.66%
Sep-19-18 12:50PM  Is DURECT Corporations (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Sep-18-18 08:00AM  DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan PR Newswire
Aug-30-18 08:00AM  DURECT Announces Receipt of $5 Million Milestone Payment from Indivior PR Newswire
Aug-27-18 04:30PM  DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference PR Newswire
Aug-21-18 07:45AM  Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-06-18 03:32PM  FDA Decision Sends Pain Therapeutics Reeling Benzinga
09:22AM  DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII PR Newswire
Aug-01-18 09:14PM  Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
05:42PM  Durect: 2Q Earnings Snapshot Associated Press
04:05PM  DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
Jul-30-18 11:42AM  Why Durect Corporation Stock Is Spiking Today Motley Fool +9.93%
08:00AM  DURECT Announces FDA Approval of Indivior's PERSERIS (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults PR Newswire
Jul-24-18 04:05PM  DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call PR Newswire
Jul-22-18 05:03PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs Benzinga
Jul-09-18 07:25AM  Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks ACCESSWIRE
Jul-05-18 12:25PM  A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year Benzinga +7.64%
Jun-30-18 06:05PM  Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates Benzinga
Jun-28-18 03:48PM  Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER Zacks -7.06%
Jun-27-18 01:29PM  Here's Why Drug Developer DURECT Corporation Plunged Today Motley Fool
08:14AM  Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading Benzinga
Jun-26-18 08:30PM  Results of FDA Advisory Committee Meeting for REMOXY® ER PR Newswire -9.38%
Jun-25-18 02:00PM  The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs Benzinga
Jun-07-18 08:10AM  New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
07:50AM  Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks ACCESSWIRE
Jun-04-18 08:00AM  DURECT Corporation Approaching PDUFA Dates and Analysts Review ACCESSWIRE
May-09-18 08:00AM  DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine) PR Newswire +7.22%
May-08-18 07:23AM  Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Heres How It Performed Lately Simply Wall St.
May-07-18 05:19AM  Edited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-02-18 06:23PM  Durect: 1Q Earnings Snapshot Associated Press
04:05PM  DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire
Apr-25-18 08:00AM  DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis PR Newswire
Apr-24-18 04:30PM  DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call PR Newswire
Mar-29-18 08:00AM  DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis PR Newswire
Mar-26-18 07:40AM  Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries Discovering Underlying Factors of Influence GlobeNewswire -5.80%
Mar-20-18 08:00AM  DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER PR Newswire +5.94%
Mar-12-18 07:58AM  Is DURECT Corporation (NASDAQ:DRRX) Undervalued? Simply Wall St.
Mar-06-18 01:36PM  Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors Benzinga +8.67%
Mar-01-18 06:31PM  Durect tops 4Q revenue forecasts Associated Press +8.20%
04:05PM  DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs PR Newswire
Feb-26-18 08:00AM  DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) PR Newswire +6.19%
Feb-22-18 04:30PM  DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call PR Newswire
Feb-20-18 08:00AM  DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) PR Newswire
Feb-14-18 08:00AM  DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics PR Newswire
Dec-13-17 08:00AM  DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot PR Newswire
Dec-12-17 08:05AM  DURECT Corporation: New Patent Revenue, Analysts Review, Earnings and Current Pipeline Progress ACCESSWIRE
Dec-11-17 01:47PM  ETFs with exposure to DURECT Corp. : December 11, 2017 Capital Cube
Dec-01-17 10:36AM  ETFs with exposure to DURECT Corp. : December 1, 2017 Capital Cube
Nov-20-17 12:15PM  ETFs with exposure to DURECT Corp. : November 20, 2017 Capital Cube +7.92%
Nov-15-17 09:00AM  Streetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double' GlobeNewswire
Nov-09-17 08:54AM  DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-08-17 05:58PM  ETFs with exposure to DURECT Corp. : November 8, 2017 Capital Cube -6.86%
12:25PM  Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Nov-02-17 05:00PM  DRRX: Focus will be Shifted to DUR-928 Programs Zacks Small Cap Research +10.13%
Nov-01-17 05:47PM  Durect tops Street 3Q forecasts Associated Press
04:05PM  DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire
Oct-26-17 04:54PM  DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call PR Newswire
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAXE JON SDirectorMay 13Buy0.719,6006,77395,000May 15 02:43 PM
SAXE JON SDirectorMay 13Buy0.7040,40028,09585,400May 14 07:01 PM
SAXE JON SDirectorMar 13Buy0.8221,30017,48041,300Mar 15 08:36 PM
SAXE JON SDirectorMar 13Buy0.823,7003,02145,000Mar 15 08:37 PM
Arenberg MichaelChief Financial OfficerMar 12Buy0.8010,0007,99024,426Mar 13 08:03 PM
BROWN JAMES EPresident & CEONov 27Buy0.8110,0008,11680,000Nov 29 05:35 PM
open in yahoo | open in reuters | open in google